{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:26Z","timestamp":1786984286843,"version":"build-2736575974"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis aimed to evaluate the efficacy and safety of renal denervation (RDN) in patients with chronic kidney disease (CKD), including those with end-stage renal disease requiring dialysis and resistant hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A comprehensive search of PubMed, Embase, Scopus, and Cochrane databases was performed from inception to August 2025. Eligible studies included randomized trials, non-randomized clinical trials, and prospective observational cohorts enrolling adult CKD patients undergoing RDN. The primary outcomes were changes in office and 24-hour ambulatory blood pressure (BP). Secondary outcomes included changes in estimated glomerular filtration rate and safety endpoints. Data were synthesized using random-effects meta-analysis, with heterogeneity assessed by\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      and publication bias evaluated by Egger test. This systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Risk of bias (RoB) was assessed using the Cochrane RoB 2 tool for randomized controlled trials and the RoB In Non-randomized Studies of Interventions-I tool for non-randomized studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twelve studies involving 202 patients with CKD stages 2 to 5, including dialysis populations, were analyzed. Pooled results demonstrated significant reductions in office systolic BP (\u221220\u2009mm Hg) and diastolic BP (\u22128\u2009mm Hg), as well as ambulatory systolic (\u221215\u2009mm Hg) and diastolic BP (\u22126\u2009mm Hg). Renal function remained stable, with no evidence of accelerated decline in estimated glomerular filtration rate. Safety analysis revealed a low incidence of complications, limited to isolated access-site events, with no excess risk of renal artery stenosis. Heterogeneity was moderate (\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200558%), while Egger test indicated no significant small-study effects (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.33).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>RDN effectively lowers BP in CKD patients without compromising renal function and demonstrates an acceptable safety profile, supporting its role as an adjunctive therapy in resistant hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050220","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:01:35Z","timestamp":1786730495000},"page":"e50220","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Blood pressure and renal outcomes after renal denervation in patients with chronic kidney disease"],"prefix":"10.1097","volume":"105","author":[{"given":"Jahanzeb","family":"Malik","sequence":"first","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Baig","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Subhan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.N.U.","family":"Sandesh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Kumari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3310-5442","authenticated-orcid":false,"given":"Abida","family":"Perveen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1681\/ASN.2011111062","article-title":"Renal denervation in moderate to severe CKD.","volume":"23","author":"Hering","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ijcard.2013.01.218","article-title":"Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease.","volume":"168","author":"Schlaich","year":"2013","journal-title":"Int J Cardiol"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/eurheartj\/eht200","article-title":"Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in CKD and resistant hypertension.","volume":"34","author":"Kiuchi","year":"2013","journal-title":"Eur Heart J"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/HJH.0000000000000556","article-title":"Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension.","volume":"33","author":"Ott","year":"2015","journal-title":"J Hypertens"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijcard.2017.01.047","article-title":"Effect of renal denervation on kidney function in patients with chronic kidney disease.","volume":"232","author":"Hering","year":"2017","journal-title":"Int J Cardiol"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/ckj\/sfx066","article-title":"Renal denervation using carbon dioxide renal angiography in patients with uncontrolled hypertension and moderate-to-severe CKD.","volume":"10","author":"Hameed","year":"2017","journal-title":"Clin Kidney J"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ekir.2017.04.012","article-title":"Endovascular renal denervation in end-stage kidney disease patients: cardiovascular protection\u2014a proof-of-concept study.","volume":"2","author":"H\u00f8ye","year":"2017","journal-title":"Kidney Int Rep"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"2054358119828388","DOI":"10.1177\/2054358119828388","article-title":"Central blood pressure and pulse-wave velocity changes post renal denervation in stage 3\u20134 CKD: the Regina RDN Study.","volume":"6","author":"Prasad","year":"2019","journal-title":"Can J Kidney Health Dis"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10157-019-01697-7","article-title":"Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single-centre experience.","volume":"23","author":"Ott","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"R10-20260817","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/HJH.0000000000002358","article-title":"Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis.","volume":"38","author":"Scalise","year":"2020","journal-title":"J Hypertens"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40620-021-00966-7","article-title":"Insights on safety and efficacy of renal artery denervation for uncontrolled-resistant hypertension in a high-risk CKD population.","volume":"34","author":"Marin","year":"2021","journal-title":"J Nephrol"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jch.14605","article-title":"Catheter-based renal denervation in Chinese patients with CKD and uncontrolled hypertension.","volume":"25","author":"Liu","year":"2023","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","article-title":"Sympathetic overactivity in patients with chronic renal failure.","volume":"327","author":"Converse","year":"1992","journal-title":"N Engl J Med"},{"issue":"6 Pt 1","key":"R14-20260817","first-page":"929","article-title":"Neurogenic factors and hypertension in chronic renal failure.","volume":"23","author":"Campese","year":"1994","journal-title":"Hypertension"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.110.164780","article-title":"Early sympathetic activation in the initial clinical stages of chronic renal failure.","volume":"57","author":"Grassi","year":"2011","journal-title":"Hypertension"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/01.CIR.0000034043.16664.96","article-title":"Sympathetic nerve activity in end-stage renal disease.","volume":"106","author":"Hausberg","year":"2002","journal-title":"Circulation"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED).","volume":"390","author":"Townsend","year":"2017","journal-title":"Lancet"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs (SPYRAL HTN-ON MED).","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal).","volume":"395","author":"Bohm","year":"2020","journal-title":"Lancet"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"RADIANCE-HTN SOLO: a randomized, sham-controlled trial of ultrasound renal denervation for hypertension.","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"Endovascular ultrasound renal denervation for hypertension (RADIANCE-HTN TRIO).","volume":"397","author":"Azizi","year":"2021","journal-title":"Lancet"},{"key":"R22-20260817","first-page":"565","article-title":"Effects of renal denervation on renal function and blood pressure in resistant hypertension.","volume":"64","author":"Kiuchi","year":"2014","journal-title":"Hypertension"},{"key":"R23-20260817","first-page":"519","article-title":"Impact of renal denervation on kidney function and long-term outcomes.","volume":"60","author":"Mahfoud","year":"2012","journal-title":"Hypertension"},{"key":"R24-20260817","first-page":"138","article-title":"Evidence and uncertainties on the role of renal denervation in hypertension and renal disease.","volume":"21","author":"Vink","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R25-20260817","first-page":"596","article-title":"Renal denervation: latest developments and future prospects.","volume":"60","author":"Persu","year":"2012","journal-title":"Curr Opin Cardiol"},{"key":"R26-20260817","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.114.03246","article-title":"Adjusted drug treatment is superior to renal sympathetic denervation in resistant hypertension.","volume":"63","author":"Fadl Elmula","year":"2014","journal-title":"Hypertension"},{"key":"R27-20260817","first-page":"1160","article-title":"Renal denervation reduces oxidative stress in hypertensive CKD rats.","volume":"87","author":"Eriguchi","year":"2015","journal-title":"Kidney Int"},{"key":"R28-20260817","first-page":"2831","article-title":"Global SYMPLICITY Registry: renal denervation in real-world practice.","volume":"40","author":"Bohm","year":"2019","journal-title":"Eur Heart J"},{"key":"R29-20260817","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jamacardio.2023.0338","article-title":"Patient-level pooled analysis of ultrasound RDN in RADIANCE trials.","volume":"8","author":"Kirtane","year":"2023","journal-title":"JAMA Cardiol"},{"key":"R30-20260817","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1161\/CIRCULATIONAHA.123.066941","article-title":"Patient-level pooled analysis of ultrasound RDN after medication escalation (RADIANCE).","volume":"149","author":"Azizi","year":"2024","journal-title":"Circulation"},{"key":"R31-20260817","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/s41440-024-01635-5","article-title":"Renal denervation using CO2 angiography in advanced CKD: feasibility and safety.","volume":"47","author":"Shinohara","year":"2024","journal-title":"Hypertens Res"},{"key":"R32-20260817","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine optimal treatment for drug-resistant hypertension (PATHWAY-2).","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"R33-20260817","first-page":"2099","article-title":"Patiromer to enable spironolactone in resistant hypertension with CKD.","volume":"380","author":"Agarwal","year":"2019","journal-title":"N Engl J Med"},{"key":"R34-20260817","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","article-title":"Resistant hypertension? Assessment of adherence by toxicological urine analysis.","volume":"31","author":"Jung","year":"2013","journal-title":"J Hypertens"},{"key":"R35-20260817","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"RADIANCE-TRIO trial: ultrasound RDN with triple fixed-dose therapy.","volume":"397","author":"Azizi","year":"2021","journal-title":"Lancet"},{"key":"R36-20260817","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes (DECLARE-TIMI 58).","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"R37-20260817","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD).","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"R38-20260817","first-page":"825","article-title":"Predictors of BP response to RDN.","volume":"58","author":"Mahfoud","year":"2011","journal-title":"Hypertension"},{"key":"R39-20260817","first-page":"33","article-title":"Predictors of BP response in SPYRAL trials.","volume":"78","author":"B\u00f6hm","year":"2021","journal-title":"Hypertension"},{"key":"R40-20260817","first-page":"364","article-title":"Impact of vascular stiffness on BP response to RDN.","volume":"37","author":"Hering","year":"2019","journal-title":"J Hypertens"},{"key":"R41-20260817","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering and risk of major CV events.","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"R42-20260817","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular outcomes.","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"R43-20260817","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"CV disease in CKD: a clinical update.","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"R44-20260817","first-page":"913","article-title":"Risk of coronary events in CKD.","volume":"81","author":"Tonelli","year":"2012","journal-title":"Kidney Int"},{"key":"R45-20260817","first-page":"1324","article-title":"Extended outcomes from SPYRAL HTN trials.","volume":"79","author":"Bohm","year":"2022","journal-title":"Hypertension"},{"key":"R46-20260817","first-page":"676","article-title":"SPYRAL HTN-OFF MED and ON MED pooled analysis.","volume":"79","author":"Kandzari","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R47-20260817","first-page":"933","article-title":"Long-term outcomes after RDN: SPYRAL extensions.","volume":"41","author":"Townsend","year":"2023","journal-title":"J Hypertens"},{"key":"R48-20260817","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jacc.2012.07.029","article-title":"Cost-effectiveness of renal denervation.","volume":"60","author":"Geisler","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R49-20260817","first-page":"213","article-title":"Optimizing patient selection for RDN.","volume":"63","author":"Persu","year":"2014","journal-title":"Hypertension"},{"key":"R50-20260817","first-page":"4632","article-title":"Expert consensus on RDN for hypertension.","volume":"43","author":"Mahfoud","year":"2022","journal-title":"Eur Heart J"},{"key":"R51-20260817","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/HYPERTENSIONAHA.125.25470","article-title":"Renal denervation in patients with moderate to severe chronic kidney disease.","volume":"82","author":"Schlaich","year":"2025","journal-title":"Hypertension"},{"key":"R52-20260817","first-page":"95","article-title":"Renal denervation for hypertension.","volume":"20","author":"B\u00f6hm","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"R53-20260817","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/02656736.2021.1916100","article-title":"Efficacy and safety of renal denervation for hypertension in patients with chronic kidney disease: a meta-analysis.","volume":"38","author":"Xia","year":"2021","journal-title":"Int J Hyperthermia"},{"key":"R54-20260817","doi-asserted-by":"crossref","first-page":"sfaf149","DOI":"10.1093\/ckj\/sfaf149","article-title":"Renal denervation in dialysis patients: long-term outcomes in a real-world setting.","volume":"18","author":"Gangemi","year":"2025","journal-title":"Clin Kidney J"},{"key":"R55-20260817","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jch.14781","article-title":"Efficacy and safety of 3D reconstruction and basket multi-electrode renal denervation (RDN) for refractory hypertensive patients with chronic kidney disease.","volume":"26","author":"Cai","year":"2024","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:00:42Z","timestamp":1786982442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050220"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":55,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050220","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"2025-09-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}